Table 5.
Eczema at 3 months (n = 88) |
Eczema at 6 months (n = 83) |
Eczema at 12 months (n = 80) |
||
---|---|---|---|---|
|
||||
Variables | AUC (95% CI) | AUC (95% CI) | AUC (95% CI) | |
Model 1 | A_24_P51322 (sense transcript) | 0.72 (0.53 – 0.91) | 0.71 (0.56 – 0.85) | 0.66 (0.48 – 0.83) |
Model 2 | A_24_P51322 + Sex | 0.87 (0.78 – 0.96) | 0.76 (0.64 – 0.88) | 0.72 (0.55 – 0.89) |
Model 3 | A_24_P51322 + FLG variants | 0.74 (0.54 – 0.93) | 0.72 (0.57 – 0.86) | 0.66 (0.49 – 0.84) |
Model 4 | A_24_P51322 + Sex + FLG variants | 0.88 (0.79 – 0.97) | 0.76 (0.64 – 0.89) | 0.72 (0.55 – 0.89) |
Model 5 | A_21_P0014075 (antisense transcript) | 0.63 (0.45 – 0.80) | 0.61 (0.45 – 0.76) | 0.60 (0.43 – 0.76) |
Model 6 | A_21_P0014075 + Sex | 0.87 (0.78 – 0.95) | 0.72 (0.59 – 0.85) | 0.71 (0.56 – 0.86) |
Model 7 | A_21_P0014075 + FLG variants | 0.78 (0.62 – 0.94) | 0.73 (0.58 – 0.88) | 0.71 (0.55 – 0.87) |
Model 8 | A_21_P0014075 + Sex + FLG variants | 0.91 (0.84–0.98) | 0.77 (0.63 – 0.90) | 0.75 (0.61 – 0.90) |
FLG, filaggrin; AUC, area under the receiver operating characteristic curve; CI, confidence interval